Courtney Marabella

Articles

Off-the-Shelf Immunotherapy ADXS-504 Under Evaluation in Biochemically Recurrent Prostate Cancer

May 12th 2021

Columbia University Irving Medical Center will partner with Advaxis, Inc. to fund a phase 1 clinical trial that seeks to examine the novel off-the-shelf neoantigen immunotherapy agent ADXS-504 in patients with biochemically recurrent prostate cancer.

Datopotamab Deruxtecan Shows Encouraging Preliminary Safety, Efficacy in TNBC

May 8th 2021

The differentiated TROP2-directed antibody-drug conjugate datopotamab deruxtecan was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer.

Bachelot Spotlights Impact of Tucatinib for CNS Metastases in HER2+ Breast Cancer

May 8th 2021

Thomas Bachelot, MD, discussed how to approach treatment of patients with HER2-positive breast cancer and CNS metastases and the impact of tucatinib in this population.

Building Off the Success Seen With Immunotherapy Strategies in NSCLC

May 7th 2021

Erminia Massarelli, MD, MS, PhD, shares key updates in immunotherapy and targeted treatment for patients with NSCLC

KATHERINE and FeDeriCa Trials Shift Standards in Early-Stage HER2+ Breast Cancer

May 6th 2021

Olwen Hahn, MD, discusses the clinical significance of the KATHERINE and FeDeriCa trials in the treatment of patients with early-stage HER2-postive breast cancer.

Quadri Calls for Integration of Surgery Into Evolving Locally Advanced Lung Cancer Paradigm

May 6th 2021

Syed M. Quadri, MD, discusses the role of surgery in early-stage and locally advanced lung cancer, as well future directions with robotic and minimally invasive surgery.

Trastuzumab Deruxtecan Under Investigation in HER2+ CRC in DESTINY-CRC02 Trial

May 3rd 2021

The first patient has received treatment with fam-trastuzumab deruxtecan-nxki in the phase 2 DESTINY-CRC02 trial, which is exploring the safety and efficacy of the antibody-drug conjugate in patients with HER2-overexpressing, BRAF wild-type, RAS-mutant or wild-type or mutant locally advanced, unresectable or metastatic colorectal cancer who have progressed following treatment with standard chemotherapy.

DPX-Survivac/Pembrolizumab Plus Cyclophosphamide to Be Examined in DLBCL

May 3rd 2021

Following feedback from the FDA, IMV Inc. and Merck have entered into an agreement to open a phase 2b clinical trial examining the combination of maveropepimut-S and pembrolizumab plus low-dose cyclophosphamide in patients with recurrent/refractory diffuse large B-cell lymphoma.

PARP Inhibitors Pave Way for Personalized Care in CRPC

April 30th 2021

Earle F. Burgess, MD, discusses optimizing the use of PARP inhibitors in the treatment of patients with advanced prostate cancer.

Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab Shows Early Promise in DSRCT

April 29th 2021

Intraperitoneal radioimmunotherapy with the anti-B7H3 murine monoclonal antibody 131I-omburtamab was well tolerated with low radiation exposure to normal organs, making it a feasible option to combine with other therapies in patients with desmoplastic small round cell tumor.